Key Takeaway from the Oncology Drug Pipeline


Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discusses the rapidly changing oncology market and what to look for in the drug pipeline. 

Transcript

This is a rapidly changing market. So as we prepare to look at what’s happening in oncology right here today and we looking into the future, we’re looking maybe 1 year out. But if we look at what we were looking at a year ago, it’s changed. So this is a rapidly changing market. We’ll continue to look at approvals much, much earlier. And one thing that’s important in the space is to look at biosimilars and specialty generics, along with how we’ve always monitored the pipeline for the oncology agents.

Most Popular

Related Articles

Although there have been links between esophageal cancer and drinking hot tea, this was the first study to examine a specific temperature.
A phase 3 study compared overall survival and cardiac safety between biosimilar trastuzumab (Ontruzant) and the reference medicine.
When combined, treatment with metformin and heme suppressed tumor growth in mice.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$